Home
6177 All Specialties
1531 Arthroplasty
615 Shoulder & Elbow
559 Osteoarthritis
558 Physical Therapy & Rehab
553 Spine
547 Sports Medicine
522 Trauma
402 General Orthopaedics
338 Foot & Ankle
287 Hand & Wrist
86 Pediatric Orthopaedics
79 Metabolic Disorders
50 Cannabis
25 Tumour
23 Peri-Operative
2 Evidence Based Medicine

Conference Reports

Summaries of the best evidence presented at major orthopaedic conferences around the world.

Exclusive Interviews

Original authors are interviewed to verify the veracity of the ACE Report and provide additional information regarding the study’s findings and methodology.

PeerView

Features the top trending OE Content from your network over the past 30 days.

OE Originals
OE Insights
Videos
OE Plus
145 COVID 19 Resource Center
7 Ace Reviews
1 OE Recommends
6 OE PeerView
75 OE Ideas
24 OE World Tour
63 OE Perspectives
44 Conferences
159 Exclusive Interviews
CME

To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:2 Issue:7 Number:612 ISSN#:2564-2537
DOWNLOAD ESPAÑOL
RCT
ACE Report #5098
Ace Report Cover Tumour

MTP-PE added to chemotherapy did not improve outcomes in metastatic osteosarcoma patients

How to Cite

OrthoEvidence. MTP-PE added to chemotherapy did not improve outcomes in metastatic osteosarcoma patients. ACE Report. 2013;2(7):612. Available from: https://myorthoevidence.com/AceReport/Report/5098

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group

Cancer. 2009 Nov 15;115(22):5339-48. doi: 10.1002/cncr.24566

Contributing Authors: AJ Chou ES Kleinerman MD Krailo Z Chen DL Betcher JH Healey Conrad EU ML Nieder MA Weiner RJ Wells RB Womer PA Meyers Children's Oncology Group

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

91 patients with metastatic osteosarcoma were randomized to receive a 3-drug treatment of chemotherapy (cisplatin, doxorubicin, and high-dose methotrexate) with or without ifosfamide. Within each group patients were further randomized to either receive liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) or not to determine whether the addition of liposomal MTP-PE to chemotherapy was eff...

To view the full content, login to your account,
or start your 30-day FREE Trial today.

FREE TRIAL Forgot Password?

Explore some of our unlocked ACE Reports below!

 Treatment of osteoarthritis: A role for education programmes?
The prevalence of intimate partner violence in women presenting to orthopaedic clinics
Osteoporosis Choice decision aid improves treatment experience of clinicians and patients
Protein-Rich nutritional supplementation shows limited efficacy in elderly hip fractures
Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.